NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II multi-institutional therapeutic study of NK-cell based nonmyeloablative
haploidentical transplantation for the treatment of high-risk acute myeloid diseases.
Enrollment will use a two-stage design. Stage 1 will enroll 15 patients unless an early
stopping rule is met. If 9 or more of these first 15 patients achieve leukemia free
neutrophil engraftment at day +28 accrual will move to stage 2. In stage 2, an additional 28
patients will be enrolled for a total of 43 patients. Patients will be followed for disease
response for 2 years.